Clinical Trials Logo

Lymphoma, B-cell clinical trials

View clinical trials related to Lymphoma, B-cell.

Filter by:

NCT ID: NCT03483688 Completed - Clinical trials for B-cell Non-Hodgkin Lymphoma

A PhaseⅠb Study Evaluating Safety and Efficacy of C-CAR011 Treatment in B- NHL Subjects

Start date: March 6, 2018
Phase: Phase 1
Study type: Interventional

This is a single arm, single-center, non-randomized study to evaluate the safety and efficacy of C-CAR011 therapy in relapsed or refractory B cell Non-Hodgkin Lymphoma (NHL).

NCT ID: NCT03483103 Completed - Clinical trials for Lymphoma, Non-Hodgkin

Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006)

Start date: July 27, 2018
Phase: Phase 2
Study type: Interventional

This is a Phase 2, open-label, multicenter study to determine the efficacy and safety of lisocabtagene maraleucel (JCAR017) in adult subjects who have relapsed from, or are refractory to, a single line of immunochemotherapy for aggressive B-cell non-Hodgkin lymphoma (NHL) and are ineligible for hematopoietic stem cell transplant (based on age, performance status, and/or comorbidities). Subjects will receive treatment with lisocabtagene maraleucel and will be followed for 2 years for safety, pharmacokinetics and biomarkers, disease status, quality of life, and survival.

NCT ID: NCT03458546 Completed - Lymphoma, B-Cell Clinical Trials

Study of Roflumilast in Combination With Standard Chemotherapy for High-risk Diffuse Large B-cell Lymphoma

Start date: May 21, 2018
Phase: Phase 1
Study type: Interventional

This study is a phase Ib, single arm, open label clinical trial that will enroll patients with untreated diffuse large B-cell lymphoma (DLCBL) at moderate or high risk for poor outcome

NCT ID: NCT03456726 Completed - Clinical trials for Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma With EZH2 Gene Mutation

Start date: April 9, 2018
Phase: Phase 2
Study type: Interventional

This is a multicenter, open-label, Phase 2 study to assess the efficacy and safety of tazemetostat in participants with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) with EZH2 gene mutation.

NCT ID: NCT03424603 Completed - Multiple Myeloma Clinical Trials

Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies

Start date: February 22, 2018
Phase: Phase 1
Study type: Interventional

First-in-human Phase 1 trial to study the safety, pharmacokinetics and preliminary efficacy of STRO-001 given intravenously every 3 weeks.

NCT ID: NCT03424122 Completed - B-cell Lymphoma Clinical Trials

INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)

Start date: July 2, 2018
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of parsaclisib when combined with rituximab, bendamustine and rituximab, or ibrutinib in participants with relapsed or refractory B-cell lymphoma.

NCT ID: NCT03415399 Completed - Lymphoma, B-Cell Clinical Trials

Clinical Study of ET190L1 ARTEMIS™ in Relapsed, Refractory B Cell Lymphoma

Start date: September 9, 2017
Phase: Phase 1
Study type: Interventional

This study is to determine the safety, including potential dose limiting toxicities, of ET190L1 ARTEMIS™ T cells and the duration of in vivo survival of ET190L1 ARTEMIS™ T cells in patients with relasped/refractory B-cell lymphoma. For patients with detectable disease, the study will also measure anti-tumor responses after ET190L1 ARTEMIS™ cell infusions.

NCT ID: NCT03399513 Completed - Clinical trials for Diffuse Large B Cell Lymphoma

Ibrutinib and Standard Immuno-Chemotherapy in Younger, High-Risk Patients With Diffuse Large B-Cell Lymphoma

R-CHOEP-brut
Start date: May 3, 2018
Phase: Phase 2
Study type: Interventional

This study will investigate if treatment results obtained with R-CHOEP in young high-risk patients with diffuse large B-cell lymphoma can be further improved by the addition of ibrutinib to this regimen.

NCT ID: NCT03378947 Completed - Clinical trials for To Characterize and Compare Clinical, Pathological and Molecular Features

EBV-associated Diffuse Large B Cell Lymphoma

Start date: June 1, 2017
Phase:
Study type: Observational

The aim of this study is to characterize and compare clinical, pathological (histology, immunophenotype) and molecular features of EBV-related GZL and DLBCL: do they belong to the same entity or to two different subtypes of EBV-related lymphoma ?

NCT ID: NCT03376958 Completed - Clinical trials for Diffuse Large B Cell Lymphoma

Apatinib for Relapsed and Refractory Diffuse Large B Cell Lymphoma

Start date: January 1, 2017
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of Apatinib for patients with Relapsed Refractory Diffuse Large B Cell Lymphoma.